Melanocortin peptide therapeutics: Historical milestones, clinical studies and commercialization

被引：72

作者：

Hadley, ME ^{[1
]}

Dorr, RT

机构：

[1] Univ Arizona, Coll Med, Dept Cell Biol & Anat, Tucson, AZ 85721 USA

[2] Univ Arizona, Coll Med, Dept Med, Tucson, AZ 85721 USA

来源：

PEPTIDES | 2006年 / 27卷 / 04期

基金：

美国国家卫生研究院;

关键词：

melanocortin; melanocyte; melanoma; melanogenesis; POMC; erectile dysfunction;

D O I：

10.1016/j.peptides.2005.01.029

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The melanocortins (MCs) are a family of multifunctional peptidergic hormones. Several superpotent, prolonged acting, enzymatically resistant, MC analogs have been designed and synthesized to help clarify the nature and role of MCs and their receptors (MCRs) in physiological functions. Two of these analogs, a linear peptide, melanotan 1, and a cyclic truncated peptide, melanotan II (MTI and MTII, respectively) have been patented and tested clinically for studies on tanning of the skin (MTI) and for diagnosis and treatment of male erectile dysfunction (MTII). A new MTII analog, PT-141 (Palatin Technologies) has initial phase I/II trials and is scheduled to enter pivotal stage III clinical trials leading to commercialization. MTI may provide a therapeutic tan with the potential to lower the risk of skin cancer. PT-141 may improve sexual functionality in both males and females. (c) 2005 Elsevier Inc. All rights reserved.

引用

页码：921 / 930

页数：10

共 46 条

[1] POTENT AND PROLONGED ACTING CYCLIC LACTAM ANALOGS OF ALPHA-MELANOTROPIN - DESIGN BASED ON MOLECULAR-DYNAMICS [J].

ALOBEIDI, F ;

CASTRUCCI, AMD ;

HADLEY, ME ;

HRUBY, VJ .

JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (12) :2555-2561

[2] DESIGN OF A NEW CLASS OF SUPERPOTENT CYCLIC ALPHA-MELANOTROPINS BASED ON QUENCHED DYNAMIC SIMULATIONS [J].

ALOBEIDI, F ;

HADLEY, ME ;

PETTITT, BM ;

HRUBY, VJ .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (09) :3413-3416

[3]

ALOBEIDI F, 1990, INT J PEPT PROT RES, V35, P228

[4] Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, melanotan-I [J].

Bhardwaj, R ;

Hadley, ME ;

Dorr, RT ;

Dvorakova, K ;

Brooks, C ;

Blanchard, J .

PHARMACEUTICAL RESEARCH, 2000, 17 (05) :593-599

[5] Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma [J].

Box, NF ;

Duffy, DL ;

Irving, RE ;

Russell, A ;

Chen, W ;

Griffiths, LR ;

Parsons, PG ;

Green, AC ;

Sturm, RA .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 116 (02) :224-229

[6] ADMINISTRATION OF MELANOTROPIC PEPTIDES DURING GESTATION IN THE RODENT [J].

DAWSON, BV ;

FORD, CA ;

HOLLOWAY, H ;

DORR, RT ;

JOHNSON, P .

TOXICOLOGY, 1993, 77 (1-2) :91-101

[7] Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response [J].

Diamond, LE ;

Earle, DC ;

Garcia, WD ;

Spana, C .

UROLOGY, 2005, 65 (04) :755-759

[8]

DORR RT, 1988, INVEST NEW DRUG, V6, P251

[9]

Dorr RT, 2000, PHOTOCHEM PHOTOBIOL, V72, P526, DOI 10.1562/0031-8655(2000)072<0526:IEEATI>2.0.CO

[10]

← 1 2 3 4 5 →